Eviva Partners, a New Nonprofit Promoting Better Understanding of Medical Evidence, Exposes Role of Andrew Wakefield in the “Manufacture of Evidence” Leading Up to Robert F. Kennedy Jr’s Confirmation Hearings
Introduces the concept of "Evidence Fluency" as a solution to the current crisis and a path towards improving healthcare overall
NEW YORK CITY, NEW YORK / ACCESS Newswire / February 10, 2025 / Eviva Partners, a pioneering healthcare initiative founded by physician-scientist Alex Morozov, announced its launch today with an innovative mission to address critical gaps in healthcare delivery through "evidence fluency" - a new framework for understanding and communicating medical evidence.
"The new US Administration is poised to have a dramatic impact on the integrity of scientific publications and medical evidence," said Alex Morozov, CEO and Founder. "An investigation over the past several days reveals a role of Andrew Wakefield in the "Manufacture of Evidence" leading up to Robert F. Kennedy Jr's Confirmation hearings. Wakefield 30 years ago was paid by another anti-vaccine lawyer, Richard Barr, to manufacture a study through research fraud showing a link between vaccines and autism. History now repeats itself, except now the anti-vaccine lawyer, Kennedy, could become in charge of US science and medicine as a whole."
Eviva Partners's solution to this crisis is simple: "Evidence Fluency." The premise is that one key, previously overlooked factor underlies the current challenges of poor and unequal outcomes and rising costs in the U.S. healthcare system: insufficient "evidence fluency" among patients, providers, and other healthcare stakeholders.
"We are a nonpartisan organization committed to helping improve health outcomes for all" said Morozov.
Eviva Partners introduces the concept of "evidence fluency" as a solution to the current crisis and a path towards improving healthcare overall, defined as having four components:
Understanding the concept of evidence as distinct from "proof;"
Ability to assess the strength of evidence;
Ability to detect manipulation;
Ability to discuss evidence with others.
Eviva Partners will focus on three areas:
Pioneering deep characterization of care gaps (both underuse and overuse), starting in hematology-oncology care, at the state level;
Developing a multi-pronged approach to increase evidence fluency through:
"Two-Eyed Seeing" methodology for bridging worldviews
K-12 evidence curriculum
A tool kit for patients and providers
Creating state and federal policy proposals to improve healthcare transparency and quality, starting with protecting the integrity of scientific literature.
The organization has assembled a distinguished advisory council including Elder Albert Marshall of the Mi'kmaw Nation, creator of the "Two-Eyed Seeing" methodology; Stephan Lewandowsky, a leading cognitive scientist at the University of Bristol, and others.
"Our preliminary surveys show that only 16% of U.S. adults correctly understand the difference between evidence and proof, while 36% have never heard the word 'evidence' used in a medical context," said Morozov. "By improving evidence fluency across the healthcare ecosystem, we can help close care gaps and ultimately improve health outcomes for all."
Initial pilot studies will focus on sickle cell disease and cancer, where care gaps are high. In addition, K-12 evidence curriculum will be piloted. Once those are completed, the organization plans to launch a nationwide public awareness campaign to promote evidence fluency.
For more information about Eviva Partners, and to read Alex Morozov's expose, "Robert F. Kennedy Jr, Andrew Wakefield and The Manufacture of Evidence," visit www.evivapartners.org, or follow Eviva Partners on Twitter, BlueSky, LinkedIn, Facebook and Instagram.
Contact Information
Alex Morozov
CEO and Founder
alex.morozov@evivapartners.org
9173751112
SOURCE: Eviva Partners
View the original press release on ACCESS Newswire
Eviva Partners

Subscribe to releases from ACCESS Newswire
Subscribe to all the latest releases from ACCESS Newswire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from ACCESS Newswire
PromiCell, Inc. presents during JP Morgan's 2026 Healthcare Conference9.1.2026 18:35:00 CET | Press release
MIAMI, FL / ACCESS Newswire / January 9, 2026 / PromiCell, Inc. (the "Company"), a clinical-stage cellular immunotherapy company uniquely positioned to advance potentially curative cell therapies for cancer patients, today announced that the Company's Chief Medical Officer, John Lee, MD, Ph.D., will present interim results of the Company's lead asset PRO CAR - 201A, a STEAP1 directed CAR T cell that is currently in the clinic as a first-in-human phase 1 trial for the treatment of metastatic castration-resistant prostate cancer (mCRPC), at Biotech Showcase 2026 in San Francisco, California on Monday, January 12, 2025 at 11:15 am PST at the Franciscan D (Ballroom Level). About PromiCell, Inc. PromiCell, is a clinical-stage cellular immunotherapy company with product candidates representing highly differentiated and novel CAR T and TCR T platforms to be developed across separate solid and hematologic types of cancer. Our pipeline of innovative products includes STEAP 1 CAR T cells, HA-1 T
Datavault AI Expands IBM Collaboration to Deploy Enterprise-Grade AI at the Edge with Available Infrastructure's SanQtum AI Platform8.1.2026 13:00:00 CET | Press release
Datavault AI will activate a secured multi-city edge AI network for real-time data tokenization, security, and monetization across New York and Philadelphia NEW YORK, NY / ACCESS Newswire / January 8, 2026 / Datavault AI Inc. (Nasdaq:DVLT), a leader in instant data monetization & enterprise digital twins, announced it will deliver enterprise-grade AI performance at the edge in New York and Philadelphia through an expanded collaboration with IBM using the SanQtum AI platform. Operated by Available Infrastructure, SanQtum AI is a fleet of synchronized micro edge data centers running IBM's watsonx portfolio of AI products on a zero-trust network. The combined deployment is designed to enable cybersecure data storage and compute, real-time data scoring, tokenization, and ultra-low-latency, across two of the most data-dense metro regions in the United States. By running Datavault AI's Information Data Exchange and DataScore agents - built with watsonx - within SanQtum AI's zero-trust edge e
Ascend Advanced Therapies - ABL Inc. Further Strengthens Executive Team as It Drives Forward an Ambitious Growth Strategy8.1.2026 13:00:00 CET | Press release
Seiga Ohmine to join as Chief Commercial Officer, Sharad Dubey as Chief Financial Officer and Patrick Lansky as Senior Vice President of Global Business Development Appointments underscore Ascend-ABL's commitment to scientific rigor, operational excellence, and strategic growth ROCKVILLE, MARYLAND / ACCESS Newswire / January 8, 2026 / Ascend Advanced Therapies - ABL Inc. today announced significant appointments to its leadership team. Seiga Ohmine Ph.D. joins as Chief Commercial Officer (CCO) Sharad Dubey CA, CPA joins as Chief Financial Officer (CFO) Patrick Lansky joins as Senior Vice President of Global Business Development These appointments reflect Ascend-ABL's focus on strengthening scientific leadership, operational discipline, and customer-centric execution as the company sharpens its positioning as a trusted CDMO partner for advanced viral modalities. Commenting on the appointments, Alessandra Rispoli, Chief Executive Officer of Ascend-ABL said, "We are making strong progress
Market Logic Announces Technology Partnership with Zappi to Accelerate Innovation with AI8.1.2026 08:00:00 CET | Press release
BERLIN, DE / ACCESS Newswire / January 8, 2026 / Market Logic Software is excited to announce a technology partnership with Zappi designed to help leading brands develop, refine, and test new product concepts faster than ever before. United by a joint agentic AI framework, this collaboration brings together advanced AI capabilities from both companies, marking a pivotal shift in how organizations execute insights-driven innovation. Through AI-to-AI integrations, linking two powerful AI platforms, enterprises can now enrich their product innovation process with a comprehensive data ecosystem. Specially trained DeepSights AI agents within Market Logic's Innovation Studio continuously monitor, analyse, and synthesize market research, news, and operational data-allowing for accelerated concept generation and more informed decision-making. With just a couple of clicks, customers can seamlessly progress to testing their concepts with real people, thanks to Zappi's real-world respondent solut
RE Royalties Announces up to a USD $9.0 Million Portfolio-Level Royalty Investment with Solaris Energy Inc.7.1.2026 22:20:00 CET | Press release
VANCOUVER, BC / ACCESS Newswire / January 7, 2026 / RE Royalties Ltd. (TSXV:RE)(OTCQX:RROYF) ("RE Royalties" or the "Company") is pleased to announce that it has entered into a definitive agreement with Solaris Energy Inc. ("Solaris") to invest up to USD $9.0 million to acquire a royalty interest (the "Royalty Purchase") in two portfolios of distributed generation ("DG") solar projects located throughout the United States. The first portfolio consists of 15 projects including 9 under construction with several nearing operation, and 6 in development, located across California, Maine, Delaware, New Hampshire and Colorado ("Portfolio 1"). The second portfolio comprises 9 more projects, the final composition of which may evolve as the projects advance ("Portfolio 2"). The transaction represents the acquisition of a portfolio level royalty on a diversified portfolio of DG solar assets and marks the exciting beginning of a new partnership between the two parties. The Royalty Purchase for Por
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom